FOLH1 and thyroid gland carcinoma: A recent pilot study [15] demonstrated the potential utility of PSMA PET in selecting papillary thyroid cancer patients for possible PSMA radioligand therapy, but this has not been evaluated in other thyroid cancer subtypes.